
Silexion Therapeutics Sets 1-for-24 Reverse Stock Split Approval
Shareholders also approved raising authorized share capital to 515,900,000 ordinary shares.
Silexion Therapeutics Corp · Nasdaq · Biological Products, (No Diagnostic Substances) · also SLXNW

Shareholders also approved raising authorized share capital to 515,900,000 ordinary shares.
No open-market insider buying or selling in the Form 4s filed since July 24, 2026.
Amendments to articles or bylaws; fiscal year change · Submission of matters to a vote of security holders · Financial statements and exhibits
AI summary, unreviewedSilexion Therapeutics Approves Authorized Share Capital Increase to 515.9 Million Shares and 1-for-24 Reverse Split
Regulation FD disclosure · Financial statements and exhibits
Entry into a material definitive agreement · Unregistered sales of equity securities · Other events · Financial statements and exhibits
Regulation FD disclosure · Financial statements and exhibits
Delisting notice / failure to meet listing standard
Submission of matters to a vote of security holders
Delisting notice / failure to meet listing standard